OSR Holdings enters $30M asset purchase agreement with subsidiary Vaximm for VXM01 IP

OSR Holdings, Inc.

$30M purchase price for VXM01 IP; payment deferred until first milestone payment under existing license (Phase 2 completion).
Milestone trigger: completion of Phase 2 study of VXM01 in glioblastoma or pancreatic cancer.
Buyer may make voluntary partial payments before milestone; full balance due on milestone date.
Related-party transaction with subsidiary Vaximm; agreement aimed at Swiss transfer pricing simplification.
Closing occurs upon full payment; no effect on asset transfer if payment default, subject to good faith resolution.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

OSR Holdings, Inc. entered into Asset Purchase Agreement with Vaximm AG valued at $30,000,000 (effective 2026-05-27).

Action: entry
Agreement: asset purchase
Counterparty: Vaximm AG
Value: $30,000,000
Effective: 2026-05-27

Exact text from the filing

On May 27, 2026, OSR Holdings, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Vaximm AG (“Vaximm”), a clinical-stage biopharmaceutical company organized under the laws of Switzerland.

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

OSR Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-064037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.